From time to time, investors are faced with some of the best names in this industry, which then become the subject of the best news and events during the period of ownership. The best choice today seems to be in the medical sector. He shows investors The main fundamental force This was noticed by other … Read more
Novo Nordisk a/s. NYSE: NVO He announced that his GLP-1 drugs in chronic obesity, with Ozempic and Wegovy brands, are no longer in deficiency. This led to the fact that the United States Products and Medications Office took half -Glutid, an active ingredient in both, from a list of drug lack of drugs on February … Read more
The advent of GLP-1 therapies has been a game changer in the medical sector in the field of weight loss and chronic obesity. The GLP-1 market is currently dominated by semaglutide (Ozempic and Wegovy), manufactured by Novo Nordisk A/S New York Stock Exchange: HBO and tirzepatide (Mounjaro and Zepbound), produced Eli Lilly and Co. New … Read more